CY1116118T1 - Κρυσταλλικες μορφες (r)-5-[3-χλωρο-4-(2,3-διυδροξυ-προποξυ)-βενζ[ζ]υλιδενιο]-2-([ζ]-προπυλιμινο)-3-o-τομυλ-θειαζολιδιν-4-ονης - Google Patents
Κρυσταλλικες μορφες (r)-5-[3-χλωρο-4-(2,3-διυδροξυ-προποξυ)-βενζ[ζ]υλιδενιο]-2-([ζ]-προπυλιμινο)-3-o-τομυλ-θειαζολιδιν-4-ονηςInfo
- Publication number
- CY1116118T1 CY1116118T1 CY20151100261T CY151100261T CY1116118T1 CY 1116118 T1 CY1116118 T1 CY 1116118T1 CY 20151100261 T CY20151100261 T CY 20151100261T CY 151100261 T CY151100261 T CY 151100261T CY 1116118 T1 CY1116118 T1 CY 1116118T1
- Authority
- CY
- Cyprus
- Prior art keywords
- propylimino
- benz
- ylidene
- dihydroxy
- propoxy
- Prior art date
Links
- -1 2,3-Dihydroxy-propoxy Chemical group 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000004218 vascular function Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η εφεύρεση αναφέρεται σε κρυσταλλικές μορφές της (R)-5-[3-χλώρο-4-(2,3-διϋδρόξυ-προπόξυ)-βενζ[Ζ]υλιδένιο]-2-([Ζ]-προπυλιμίνο)-3-ο-τολυλ-θειαζολιδιν-4-όνης, σε διαδικασίες για τη παρασκευή τους, σε φαρμακευτικές συνθέσεις που περιέχουν τις αναφερόμενες κρυσταλλικές μορφές, και στη χρήση τους ως ενώσεις που βελτιώνουν τη λειτουργία των αγγείων και ως ανοσοτροποποιητικών παραγόντων, είτε μόνες τους ή σε συνδυασμό με άλλες δραστικές ενώσεις ή θεραπευτικές αγωγές.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0819182.7A GB0819182D0 (en) | 2008-10-20 | 2008-10-20 | Crystalline forms |
| EP09741441.1A EP2344465B1 (en) | 2008-10-20 | 2009-10-19 | Crystalline forms of (r) -5- [3-chloro-4-( 2, 3-dihydroxy-propoxy)-benz [z]ylidene]-2- [z]-propylimino) -3-o-tolyl-thiazolidin-4-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116118T1 true CY1116118T1 (el) | 2017-02-08 |
Family
ID=40097688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100261T CY1116118T1 (el) | 2008-10-20 | 2015-03-13 | Κρυσταλλικες μορφες (r)-5-[3-χλωρο-4-(2,3-διυδροξυ-προποξυ)-βενζ[ζ]υλιδενιο]-2-([ζ]-προπυλιμινο)-3-o-τομυλ-θειαζολιδιν-4-ονης |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9062014B2 (el) |
| EP (1) | EP2344465B1 (el) |
| JP (1) | JP5008777B2 (el) |
| KR (1) | KR101409597B1 (el) |
| CN (1) | CN102177144B (el) |
| AR (1) | AR073904A1 (el) |
| AU (1) | AU2009305980C1 (el) |
| BR (1) | BRPI0919673B1 (el) |
| CA (1) | CA2740313C (el) |
| CL (1) | CL2011000867A1 (el) |
| CY (1) | CY1116118T1 (el) |
| DK (1) | DK2344465T3 (el) |
| ES (1) | ES2534333T3 (el) |
| GB (1) | GB0819182D0 (el) |
| HR (1) | HRP20150391T1 (el) |
| IL (1) | IL212351A (el) |
| MA (1) | MA32797B1 (el) |
| MX (1) | MX2011003988A (el) |
| MY (1) | MY160703A (el) |
| NZ (1) | NZ592854A (el) |
| PL (1) | PL2344465T3 (el) |
| PT (1) | PT2344465E (el) |
| RU (1) | RU2519548C2 (el) |
| SI (1) | SI2344465T1 (el) |
| TW (1) | TWI462911B (el) |
| WO (1) | WO2010046835A1 (el) |
| ZA (1) | ZA201103691B (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| RU2379299C2 (ru) | 2003-11-21 | 2010-01-20 | Актелион Фармасьютиклз Лтд | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов |
| MX2009005048A (es) * | 2006-11-23 | 2009-05-25 | Actelion Pharmaceuticals Ltd | Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona. |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| SI2278960T2 (sl) | 2008-03-17 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Režim odmerjanja za selektivni agonist receptorja sip1 |
| BR122021008918B1 (pt) * | 2011-06-02 | 2021-08-10 | Chinoin Zrt | Forma cristalina ii de bimatoproposta e processo para a preparação da mesma |
| RS60408B1 (sr) | 2012-08-17 | 2020-07-31 | Actelion Pharmaceuticals Ltd | Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku |
| MX379273B (es) | 2014-12-11 | 2025-03-11 | Actelion Pharmaceuticals Ltd | Regimen de dosificación para un agonista selectivo de receptor s1p1. |
| MA41139A (fr) * | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| JP6691218B2 (ja) * | 2015-12-25 | 2020-04-28 | クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． | 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法 |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11220488B2 (en) | 2017-09-19 | 2022-01-11 | Teva Pharmaceuticals International Gmbh | Crystalline polymorph of Ponesimod |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| EP4003338A1 (en) | 2019-07-22 | 2022-06-01 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| CN114599363A (zh) | 2019-10-31 | 2022-06-07 | 爱杜西亚药品有限公司 | Cxcr7拮抗剂与s1p1受体调节剂的组合 |
| WO2021143414A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种ponesimod的晶型及其制备方法和用途 |
| BR112022017754A2 (pt) | 2020-03-06 | 2022-10-18 | Actelion Pharmaceuticals Ltd | Métodos para retardar a perda de volume cerebral |
| US20240368094A1 (en) | 2021-08-17 | 2024-11-07 | Teva Czech Industries S.R.O | Polymorphs of ponesimod |
| CA3220715A1 (en) | 2021-10-11 | 2023-04-20 | Krista Spiller | Methods of treating multiple sclerosis |
| WO2023061939A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| EP4415699A1 (en) | 2021-10-11 | 2024-08-21 | Laboratoires Juvise Pharmaceuticals | Methods of treating multiple sclerosis |
| US12357616B2 (en) | 2021-10-11 | 2025-07-15 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
| WO2023079079A1 (en) | 2021-11-05 | 2023-05-11 | Actelion Pharmaceuticals Ltd | Methods for treating multiple sclerosis |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| US20240261268A1 (en) | 2022-02-11 | 2024-08-08 | Vanda Pharmaceuticals Inc. | Methods of slowing an increase in brain ventricular volume |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA79793C2 (en) * | 2002-07-10 | 2007-07-25 | Applied Research Systems | Azolidinone-vinyl fused-benzene derivatives |
| WO2005037424A1 (en) * | 2003-10-06 | 2005-04-28 | Solvias Ag | Process for the parallel detection of crystalline forms of molecular solids |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| RU2379299C2 (ru) * | 2003-11-21 | 2010-01-20 | Актелион Фармасьютиклз Лтд | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| MX2009005048A (es) | 2006-11-23 | 2009-05-25 | Actelion Pharmaceuticals Ltd | Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona. |
| SI2278960T2 (sl) | 2008-03-17 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Režim odmerjanja za selektivni agonist receptorja sip1 |
-
2008
- 2008-10-20 GB GBGB0819182.7A patent/GB0819182D0/en not_active Ceased
-
2009
- 2009-10-19 DK DK09741441.1T patent/DK2344465T3/en active
- 2009-10-19 BR BRPI0919673-0A patent/BRPI0919673B1/pt active IP Right Grant
- 2009-10-19 TW TW098135296A patent/TWI462911B/zh active
- 2009-10-19 JP JP2011531624A patent/JP5008777B2/ja active Active
- 2009-10-19 ES ES09741441.1T patent/ES2534333T3/es active Active
- 2009-10-19 MX MX2011003988A patent/MX2011003988A/es active IP Right Grant
- 2009-10-19 PT PT97414411T patent/PT2344465E/pt unknown
- 2009-10-19 MY MYPI2011001728A patent/MY160703A/en unknown
- 2009-10-19 HR HRP20150391TT patent/HRP20150391T1/hr unknown
- 2009-10-19 AR ARP090104010A patent/AR073904A1/es unknown
- 2009-10-19 SI SI200931161T patent/SI2344465T1/sl unknown
- 2009-10-19 EP EP09741441.1A patent/EP2344465B1/en active Active
- 2009-10-19 WO PCT/IB2009/054592 patent/WO2010046835A1/en not_active Ceased
- 2009-10-19 KR KR1020117011262A patent/KR101409597B1/ko active Active
- 2009-10-19 AU AU2009305980A patent/AU2009305980C1/en active Active
- 2009-10-19 NZ NZ592854A patent/NZ592854A/xx unknown
- 2009-10-19 US US13/125,102 patent/US9062014B2/en active Active
- 2009-10-19 RU RU2011119898/04A patent/RU2519548C2/ru active
- 2009-10-19 CN CN200980141327.8A patent/CN102177144B/zh active Active
- 2009-10-19 PL PL09741441T patent/PL2344465T3/pl unknown
- 2009-10-19 CA CA2740313A patent/CA2740313C/en active Active
-
2011
- 2011-04-14 IL IL212351A patent/IL212351A/en active IP Right Grant
- 2011-04-19 CL CL2011000867A patent/CL2011000867A1/es unknown
- 2011-05-13 MA MA33846A patent/MA32797B1/fr unknown
- 2011-05-19 ZA ZA2011/03691A patent/ZA201103691B/en unknown
-
2015
- 2015-03-13 CY CY20151100261T patent/CY1116118T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116118T1 (el) | Κρυσταλλικες μορφες (r)-5-[3-χλωρο-4-(2,3-διυδροξυ-προποξυ)-βενζ[ζ]υλιδενιο]-2-([ζ]-προπυλιμινο)-3-o-τομυλ-θειαζολιδιν-4-ονης | |
| CY1124855T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
| CY1117615T1 (el) | Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης | |
| CY1113267T1 (el) | Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1 | |
| EA201791254A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| CY1117941T1 (el) | Υψηλης συγκεντρωσης φapμαkeytika σκευασματα που περιλαμβανουν το αντισωμα κatα cd20 | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| EA201170441A1 (ru) | Терапевтические противовирусные пептиды | |
| CY1109673T1 (el) | Συνεργεια των gos και της πολυφρουκτοζης | |
| EA201070786A1 (ru) | Бензофуропиримидиноны | |
| DK2203430T3 (da) | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) | |
| CL2011001333A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| CY1114669T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
| CY1120435T1 (el) | Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c | |
| CL2007000680A1 (es) | Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc. | |
| CY1116274T1 (el) | Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας | |
| BR122020011180B8 (pt) | formulações injetáveis de compostos de tetraciclina | |
| EA201290229A1 (ru) | Производные спиролактама и их применение |